Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14686300 | 1.00 | OGA (0.42) | OGASCN9ACNR2GPR119CYP3A4 | |
| SCHEMBL514847 | 0.88 | GPR119 (0.50) | OGASCN9ACNR2GPR119CYP3A4 | |
| SCHEMBL515814 | 0.88 | CNR2 (0.48) | SCN9ACNR2GPR119CYP3A4CYP2C19 | |
| SCHEMBL514135 | 0.86 | SCN9A (0.42) | SCN9ACNR2GPR119CYP3A4CYP2C19 | |
| SCHEMBL513940 | 0.86 | CNR2 (0.47) | SCN9ACNR2GPR119CYP3A4CYP2C19 | |
| SCHEMBL513556 | 0.86 | SCN9A (0.41) | SCN9ACNR2GPR119CYP3A4CYP2C19 | |
| SCHEMBL514449 | 0.85 | CNR2 (0.44) | SCN9ACNR2GPR119CYP3A4CYP2C19 | |
| SCHEMBL514608 | 0.84 | SCN9A (0.40) | SCN9ACNR2GPR119CYP3A4CYP2C19 | |
| SCHEMBL514649 | 0.84 | GPR119 (0.56) | SCN9AGPR119CYP3A4CYP2C19 | |
| SCHEMBL514402 | 0.83 | SCN9A (0.40) | SCN9ACNR2GPR119CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742117-B2 | Oxime derivatives | CADILA HEALTHCARE LIMITED (IN) | 2014-06-03 | — | — | US | claimed |
| EP-2379542-B1 | NOVEL OXIME DERIVATIVES | CADILA HEALTHCARE LTD (IN) | 2013-02-13 | — | — | EP | claimed |
| US-20120028996-A1 | NOVEL OXIME DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2012-02-02 | — | — | US | claimed |
| US-8742117-B2 | Oxime derivatives | CADILA HEALTHCARE LIMITED (IN) | 2014-06-03 | — | — | US | disclosed |
| EP-2379542-B1 | NOVEL OXIME DERIVATIVES | CADILA HEALTHCARE LTD (IN) | 2013-02-13 | — | — | EP | disclosed |
| US-20120028996-A1 | NOVEL OXIME DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028996-A1 | NOVEL OXIME DERIVATIVES | CYP11B2, CYP11B1, PYGL | OGA 274/4885SCN9A 2182/4885CNR2 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.